These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 16909692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS.
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK.
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J, Rempinski D, O'Neill W, Kahn J.
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA, Jensen LA, Ferguson IA, Williams RG.
    Heart Lung; 2007 Jun; 36(3):195-204. PubMed ID: 17509426
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.
    Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W.
    N Engl J Med; 2000 Jul 20; 343(3):180-4. PubMed ID: 10900277
    [Abstract] [Full Text] [Related]

  • 12. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O.
    Am Heart J; 2007 Sep 20; 154(3):539-44. PubMed ID: 17719303
    [Abstract] [Full Text] [Related]

  • 13. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, Piccaluga E, Danna P, Scorza D.
    Nephrol Dial Transplant; 2009 Oct 20; 24(10):3103-7. PubMed ID: 19549691
    [Abstract] [Full Text] [Related]

  • 14. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O.
    Int J Cardiol; 2012 Mar 22; 155(3):418-23. PubMed ID: 21106264
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
    Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F.
    Am J Cardiol; 2010 Feb 01; 105(3):288-92. PubMed ID: 20102936
    [Abstract] [Full Text] [Related]

  • 16. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H, Lee MH.
    Int J Cardiol; 2010 Feb 04; 138(3):239-45. PubMed ID: 18793808
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M.
    J Cardiol; 2010 Mar 04; 55(2):174-9. PubMed ID: 20206069
    [Abstract] [Full Text] [Related]

  • 18. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ.
    Am Heart J; 2006 May 04; 151(5):1032.e9-12. PubMed ID: 16644332
    [Abstract] [Full Text] [Related]

  • 19. Contrast-induced nephrotoxicity in renal allograft recipients.
    Ahuja TS, Niaz N, Agraharkar M.
    Clin Nephrol; 2000 Jul 04; 54(1):11-4. PubMed ID: 10939751
    [Abstract] [Full Text] [Related]

  • 20. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV.
    Circulation; 2004 Nov 02; 110(18):2837-42. PubMed ID: 15492300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.